Beta Drugs Limited (BETA) — Announcement | 27 July 2026

27 July 2026 · NSE Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Beta Drugs unveiled FY26 growth strategy with oncology dominance and IVF market entry via Nivian acquisition.

🔄 What Changed

20.75% FY26 revenue growth, 21.83% Q1-FY27 EBITDA margin, 31.03% debt-to-equity ratio

🔮 What's Next

FY27 revenue growth guidance of 20-25% and target of 50% revenue from branded products by FY30

💡 Investor Takeaway

Beta Drugs is strategically diversifying into IVF and dermatology while maintaining oncology leadership with strong financial metrics.

Beta Drugs Limited presented its FY26 investor deck highlighting robust growth across oncology, IVF, and dermatology segments. Revenue reached INR 3,848 crores in FY26 with 20.75% YoY growth, driven by 36% branded formulations contribution. The company secured INR 117 crores via CCDs from global investors in 2024 and acquired 66.09% of Nivian Life Sciences to enter the high-growth IVF market. Consolidated EBITDA margin improved to 21.83% in Q1-FY27, reflecting stronger branded and export performance. The firm maintains a healthy ROCE of 107% and debt-to-equity of 31.03%, supporting its Vision 2030 strategy to diversify beyond oncology.

📄 View Original Announcement (PDF)

📊 Stock Analysis — BETA ✨ Ask AI About This

About Beta Drugs Limited (BETA)

Healthcare · Pharmaceuticals · Listed on NSE

ROE: 18.6%ROCE: 19.2%

View full BETA stock details →

📡 Get AI alerts when BETA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track BETA — Free

💡 Ask AI about this filing

"How will Nivian acquisition impact profitability timelines?""What is the revenue contribution split between oncology and new segments?""When will IVF segment reporting begin under consolidated results?"

Ask AI Free →

📊 More BETA filings

🟡 Board Meeting — 18 August 2026Beta Drugs Limited announced the board approved the allotment of 35,383 bonus equity shares to CCD h...
Announcement — 23 July 2026Beta Drugs Limited issued revised Limited Review Reports with UDIN to correct an oversight in its st...
Financial Results — 22 July 2026No summary available
🟡 deviation variation — 20 July 2026Beta Drugs Limited confirmed no deviation in the use of funds from its November 2024 preferential is...
🟡 Board Meeting — 20 July 2026Beta Drugs Limited announced its Q1FY27 results on 20 July 2026, reporting consolidated revenue of ₹...

See all BETA filings →

🔥 Also filed on 27 July 2026

FAIRCHEMORFairchem Organics LimitedFinancial Results MPHASISMphasiS LimitedInsider Trading NTPCNTPC LimitedCorporate Action CCLCCL Products (India) LimitedCorporate Action ITIITI LimitedAnnouncement SHRIRAMFINShriram Finance LimitedFinancial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when BETA files new disclosures

Track BETA filings, board meetings, and corporate actions. Free email alerts at 5 PM.